CENPI Drives Breast Cancer Progression via Wnt/β-Catenin Signaling

Study Background and Research Question

Breast cancer (BCa) remains the most prevalent malignancy among women globally, accounting for approximately 2.3 million new diagnoses and 665,000 deaths in 2022 alone (source: paper). Despite advances in therapy, treatment resistance and tumor heterogeneity continue to undermine patient outcomes, underscoring the pressing need for new molecular targets. Chromosomal instability is a hallmark of aggressive BCa subtypes, particularly triple-negative breast cancer, and proteins that regulate chromosome segregation have emerged as points of interest. Centromere Protein I (CENPI), a core mediator of centromere function and chromosome division, has been implicated as an oncogenic driver in several cancers, but its functional and mechanistic role in breast cancer remained unclear prior to this study.

Key Innovation from the Reference Study

The central innovation of Wu et al. (2025) lies in establishing a direct mechanistic link between CENPI overexpression and activation of the Wnt/β-catenin signaling pathway in breast cancer cells (source: paper). The research systematically demonstrates that CENPI is not only aberrantly upregulated in BCa tissues but also functionally propels tumorigenic phenotypes by modulating this canonical pathway—long recognized for its roles in proliferation, stemness, and metastasis. This positions CENPI as a dual biomarker and functional driver, opening avenues for targeted intervention.

Methods and Experimental Design Insights

To dissect the role of CENPI, the authors employed an integrative pipeline:

• Clinical Data Mining: Analysis of The Cancer Genome Atlas (TCGA) BCa dataset to correlate CENPI expression with clinical outcomes.
• Tissue Validation: Immunohistochemical staining in three human BCa specimens confirmed overexpression at the protein level.
• Cellular Functional Assays: Gain- and loss-of-function experiments in BCa cell lines evaluated the impact of CENPI on proliferative and malignant phenotypes.
• In Vivo Xenografts: Mouse models substantiated CENPI's role in promoting tumorigenesis.
• Molecular Mechanism Discovery: RNA sequencing and bioinformatics identified pathway modulation, while Western blotting, immunofluorescence, and bioluminescence reporter assays (specifically the TOP/FOP flash Dual Luciferase Reporter Gene System) validated Wnt/β-catenin pathway activation.

This comprehensive approach, notably the use of dual luciferase reporter assays, enabled sensitive and high-throughput quantification of transcriptional activity downstream of pathway modulation, a strategy increasingly adopted in gene expression regulation research (source: internal_article).

Protocol Parameters

• assay | Dual Luciferase Reporter Gene System | applicability | Enables simultaneous quantification of Wnt/β-catenin-responsive (firefly) and control (Renilla) luciferase activities in BCa cell lines | workflow_recommendation
• firefly luciferase substrate | ~0.5 mM luciferin | optimized for mammalian cells | Ensures maximal signal-to-noise in bioluminescence reporter assay | workflow_recommendation
• reporter plasmid amount | 500 ng per well (24-well format) | BCa cell transfection | Balances expression efficiency with cellular viability | workflow_recommendation
• incubation time post-transfection | 24–48 hours | gene expression regulation studies | Captures dynamic transcriptional responses to CENPI manipulation | workflow_recommendation
• serum content in media | 1–10% (RPMI 1640, DMEM, MEMα, F12) | compatible with dual luciferase assay kits | Maintains cell health during reporter assays | product_spec

Core Findings and Why They Matter

Wu et al. report that CENPI is significantly overexpressed in breast cancer tissues compared to normal controls, with high expression correlating strongly with advanced disease stage and poor overall prognosis (source: paper). Functional studies reveal that CENPI augments cellular proliferation, migration, and other malignant phenotypes both in vitro and in vivo. Mechanistically, RNA-seq and downstream validation pinpoint upregulation of the Wnt/β-catenin pathway as the key axis through which CENPI exerts its effects, as evidenced by increased β-catenin levels and heightened activity in TOP/FOP luciferase reporter assays. These findings reinforce the relevance of centromere-associated proteins in gene expression regulation and tumor biology, highlighting the robust utility of bioluminescence reporter assays for dissecting such mechanisms (source: internal_article).

Comparison with Existing Internal Articles

Several internal resources have explored the deployment of the Dual Luciferase Reporter Gene System in cancer signaling research. Notably, internal analyses emphasize the system's sensitivity, high-throughput luciferase detection capability, and minimal workflow complexity for mammalian cell culture luciferase assays (source: internal_article; internal_article). The current study extends these insights by demonstrating the system's pivotal role in quantifying dynamic transcriptional regulation in the context of oncogenic pathway activation. While prior internal content focused on cAMP–PKA–CREB signaling or general transcriptional activation, Wu et al. provide direct evidence of its value in Wnt/β-catenin pathway analysis, underlining the versatility of dual luciferase reporter systems for mechanistic oncology research.

Limitations and Transferability

While this work provides robust evidence for CENPI’s oncogenic role, several limitations are noted. The initial tissue validation was limited to three patient samples, potentially restricting the generalizability of expression findings; larger cohorts are warranted. Xenograft models, while informative, may not fully recapitulate the complex tumor microenvironment of human breast cancer. Additionally, the mechanistic interrogation focused predominantly on the Wnt/β-catenin pathway—other downstream or parallel signaling pathways may also contribute to CENPI-driven malignancy but were not explored in detail (source: paper). As with all preclinical studies, further validation in clinical specimens and settings is essential before translation to therapeutic development.

Research Support Resources

To replicate or extend the transcriptional regulation studies described, researchers can employ dual-reporter gene assays for high-throughput and sensitive detection of pathway activity. The Dual Luciferase Assay System (SKU: K1136) from APExBIO is optimized for quantifying firefly and Renilla luciferase signals in mammalian cell culture, supporting workflows that interrogate gene expression regulation and pathway modulation. The system’s compatibility with common cell culture media and direct cell lysis protocol can streamline reporter assays in complex experimental designs (source: product_spec).